Design of optimized hypoxia-activated prodrugs using pharmacokinetic/pharmacodynamic modeling.

Foehrenbacher, Annika; Secomb, Timothy W; Wilson, William R; Hicks, Kevin O

Foehrenbacher, Annika; Secomb, Timothy W; Wilson, William R; Hicks, Kevin O.

Afiliación

Foehrenbacher A; Auckland Cancer Society Research Centre, The University of Auckland , Auckland , New Zealand.
Secomb TW; Department of Physiology, University of Arizona , Tucson, AZ , USA.
Wilson WR; Auckland Cancer Society Research Centre, The University of Auckland , Auckland , New Zealand.
Hicks KO; Auckland Cancer Society Research Centre, The University of Auckland , Auckland , New Zealand.

Front Oncol ; 3: 314, 2013 Dec 27.

Article en En | MEDLINE | ID: mdl-24409417

Palabras clave

PR-104; bystander effect; extravascular drug transport; hypoxia-activated prodrugs; pharmacokinetic/pharmacodynamic modeling; rational drug design; tirapazamine; tumor hypoxia

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Oncol Año: 2013 Tipo del documento: Article País de afiliación: Nueva Zelanda Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google